查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420989

青光眼治疗市场（药物类别：前列腺素、β 受体阻断剂、α 激动剂、碳酸酐酶抑制剂、组合药物和胆碱能药物）- 全球产业分析、规模、份额、成长、趋势和预测， 2023-2031 年

Glaucoma Therapeutics Market (Drug Class: Prostaglandins, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Combination Medications, and Cholinergics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10个工作天内

价格

青光眼治疗市场 - 报告范围

TMR 关于全球青光眼治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球青光眼治疗市场的收入2017-2031年期间，考虑2023年为基准年，2031年为预测年。该报告也提供了2023年至2031年全球青光眼治疗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解青光眼治疗市场。

市场概况
2023年市场价值 83 亿美元
2031 年市场价值 135 亿美元
CAGR 5.5%

该报告深入探讨了全球青光眼治疗市场的竞争格局。全球青光眼治疗市场的主要参与者已经确定，并且每位参与者都根据不同的属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球青光眼治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2023-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2023-2031
    • 前列腺素
    • β受体阻断剂
    • α激动剂
    • 联合用药
    • 胆碱能
  • 市场吸引力分析：依药品类别

第 7 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2023-2031
    • 医院
    • 眼科诊所
    • 门诊手术中心
  • 市场吸引力分析：按最终用户

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2023-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第 14 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Santen Pharmaceutical Co., Ltd.
    • Bausch Health Companies Inc.
    • Alcon
Product Code: TMRGL16406

Glaucoma Therapeutics Market - Scope of Report

TMR's report on the global glaucoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global glaucoma therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glaucoma therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the glaucoma therapeutics market.

Market Snapshot
Market Value in 2023US$ 8.3 Bn
Market Value in 2031US$ 13.5 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global glaucoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global glaucoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global glaucoma therapeutics market.

The report delves into the competitive landscape of the global glaucoma therapeutics market. Key players operating in the global glaucoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global glaucoma therapeutics market profiled in this report.

Key Questions Answered in Global glaucoma therapeutics Market Report:

  • What is the sales/revenue generated by glaucoma therapeutics across all regions during the forecast period?
  • What are the opportunities in the global glaucoma therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Glaucoma Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global glaucoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global glaucoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global glaucoma therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Glaucoma Therapeutics Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Glaucoma Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2023-2031
    • 6.3.1. Prostaglandins
    • 6.3.2. Beta Blockers
    • 6.3.3. Alpha Agonists
    • 6.3.4. Combination Medications
    • 6.3.5. Cholinergics
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Glaucoma Therapeutics Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2023-2031
    • 7.3.1. Hospitals
    • 7.3.2. Ophthalmic Clinics
    • 7.3.3. Ambulatory Surgical Centers
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Glaucoma Therapeutics Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Glaucoma Therapeutics Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Drug Class, 2023-2031
    • 9.3.1. Prostaglandins
    • 9.3.2. Beta Blockers
    • 9.3.3. Alpha Agonists
    • 9.3.4. Combination Medications
    • 9.3.5. Cholinergics
  • 9.4. Market Value Forecast, by End-user, 2023-2031
    • 9.4.1. Hospitals
    • 9.4.2. Ophthalmic Clinics
    • 9.4.3. Ambulatory Surgical Centers
  • 9.5. Market Value Forecast, by Country, 2023-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Drug Class
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Glaucoma Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2023-2031
    • 10.3.1. Prostaglandins
    • 10.3.2. Beta Blockers
    • 10.3.3. Alpha Agonists
    • 10.3.4. Combination Medications
    • 10.3.5. Cholinergics
  • 10.4. Market Value Forecast, by End-user, 2023-2031
    • 10.4.1. Hospitals
    • 10.4.2. Ophthalmic Clinics
    • 10.4.3. Ambulatory Surgical Centers
  • 10.5. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2023-2031
    • 11.3.1. Prostaglandins
    • 11.3.2. Beta Blockers
    • 11.3.3. Alpha Agonists
    • 11.3.4. Combination Medications
    • 11.3.5. Cholinergics
  • 11.4. Market Value Forecast, by End-user, 2023-2031
    • 11.4.1. Hospitals
    • 11.4.2. Ophthalmic Clinics
    • 11.4.3. Ambulatory Surgical Centers
  • 11.5. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Glaucoma Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2023-2031
    • 12.3.1. Prostaglandins
    • 12.3.2. Beta Blockers
    • 12.3.3. Alpha Agonists
    • 12.3.4. Combination Medications
    • 12.3.5. Cholinergics
  • 12.4. Market Value Forecast, by End-user, 2023-2031
    • 12.4.1. Hospitals
    • 12.4.2. Ophthalmic Clinics
    • 12.4.3. Ambulatory Surgical Centers
  • 12.5. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2023-2031
    • 13.3.1. Prostaglandins
    • 13.3.2. Beta Blockers
    • 13.3.3. Alpha Agonists
    • 13.3.4. Combination Medications
    • 13.3.5. Cholinergics
  • 13.4. Market Value Forecast, by End-user, 2023-2031
    • 13.4.1. Hospitals
    • 13.4.2. Ophthalmic Clinics
    • 13.4.3. Ambulatory Surgical Centers
  • 13.5. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. AbbVie Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Merck & Co., Inc.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Pfizer Inc.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Novartis AG
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Santen Pharmaceutical Co., Ltd.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Bausch Health Companies Inc.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Alcon
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview

List of Tables

  • Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031
  • Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2023-2031
  • Table 04: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2023-2031
  • Table 05: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 06: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031
  • Table 07: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 08: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 9: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031
  • Table 10: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 11: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 12: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031
  • Table 13: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 15: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031
  • Table 16: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 17: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023-2031
  • Table 18: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023-2031

List of Figures

  • Figure 01: Global Glaucoma Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Glaucoma Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022
  • Figure 03: Global Glaucoma Therapeutics Market Value Share, by Drug Class, 2022
  • Figure 04: Global Glaucoma Therapeutics Market Revenue (US$ Mn), by End-user, 2022
  • Figure 05: Global Glaucoma Therapeutics Market Value Share, by End-user, 2022
  • Figure 06: Global Glaucoma Therapeutics Market Value Share, by Region, 2022
  • Figure 07: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 8: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 9: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 10: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 11: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 12: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 14: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 15: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Glaucoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 17: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 18: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 19: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 20: North America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 21: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 22: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 23: Europe Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 24: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 25: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 26: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 27: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 29: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 30: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 31: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 32: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 33: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 34: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 35: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 36: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 37: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 38: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 39: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 40: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 41: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 42: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 43: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 45: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 46: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
  • Figure 47: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031